LONDON – Destiny Pharma Ltd. is to go public on the Alternative Investment Market (AIM) in London next month, raising around £10 million to fund a phase IIb trial of its first-in-class antibiotic XF-73, in the prevention of post-surgical methicillin-resistant Staphylococcus aureus.